Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted
Source: SeekingAlpha
2025-10-10 17:18:54 ET
Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-1840 and a positive result from its imaging and dosimetry candidate MNPR-101-Zr are responsible for the remarkable turnaround. With an operating runway through YE26, an anticipated NDA filing for ALXN-1840 in early 2026, along with new and positive Street sponsorship, the surge in Monopar merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted
Eton Pharmaceutcials Inc.
NASDAQ: ETON
ETON Trading
5.65% G/L:
$18.51 Last:
128,591 Volume:
$17.74 Open:
ETON Latest News
March 03, 2026 04:30:00 pm
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 02, 2026 07:27:44 am
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
February 25, 2026 01:47:00 pm
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
February 20, 2026 06:50:00 am
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
ETON Stock Data
$408,699,233
22,518,684
14.05%
24
N/A
Pharmaceuticals
Healthcare
US
Deer Park
